Concentrix (NASDAQ:CNXC) 株価情報

Concentrix

CNX Coal Resources

Concentrix Corp is a technology enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Frances and Others. Maximum revenue is from Technology and consumer electronics industry and geographically from Philippines.

Concentrix Corp

Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $58.0, a high estimate of $65.00, and a low estimate of $54.00. Experiencing a 3.73% decline, the current average is now lower than the previous average price target of $60.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1749502875_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Concentrix by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruplu Bhattacharya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Ruplu Bhattacharya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$59.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Concentrix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Concentrix compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Concentrix's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Concentrix's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CNXC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Concentrix analyst ratings.</a>
<h2>Discovering Concentrix: A Closer Look</h2>
Concentrix Corp is a technology enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Frances and Others. Maximum revenue is from Technology and consumer electronics industry and geographically from Philippines.
<h3>Concentrix: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Concentrix's revenue growth over a period of 3M has faced challenges. As of 28 February, 2025, the company experienced a revenue decline of approximately -1.27%. This indicates a decrease in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Concentrix's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 2.82%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Concentrix's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.66%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Concentrix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.56%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.22.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CNXC

Analyst Expectations For Concentrix's Future

B of A Securities analyst Ruplu Bhattacharya maintains Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) with a Neutral and raises the price target from $59 to $65.

News

Price Target

B of A Securities Maintains Neutral on Concentrix, Raises Price Target to $65

On April 17, a recent SEC filing unveiled that Olivier Duha, Director at Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) made an insider sell.
What Happened: Duha's decision to sell 108,843 shares of Concentrix was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001803599/000180359925000113//Archives/edgar/data/1803599/000180359925000113/0001803599-25-000113-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total value of the sale is $5,274,970.
The latest market snapshot at Friday morning reveals Concentrix shares down by 0.25%, trading at $47.33.
<h3>Delving into Concentrix's Background</h3>
Concentrix Corp is a technology enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Frances and Others. Maximum revenue is from Technology and consumer electronics industry and geographically from Philippines.
<h3>Breaking Down Concentrix's Financial Performance</h3>
Decline in Revenue: Over the 3 months period, Concentrix faced challenges, resulting in a decline of approximately -1.27% in revenue growth as of 28 February, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 36.08%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Concentrix's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 1.04.
</li>
</ul>
Debt Management: Concentrix's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.22.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 11.89, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.32, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 5.77, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001803599">Check Out The Full List Of Concentrix's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Insider Selling: Olivier Duha Unloads $5.27M Of Concentrix Stock

Ratings for Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $61.75, along with a high estimate of $80.00 and a low estimate of $54.00. Experiencing a 12.41% decline, the current average is now lower than the previous average price target of $70.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1743105689_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Concentrix. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Ruplu Bhattacharya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$59.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Concentrix. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Concentrix compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Concentrix's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Concentrix's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CNXC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Concentrix analyst ratings.</a>
<h2>About Concentrix</h2>
Concentrix Corp is a technology enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Frances and Others. Maximum revenue is from Technology and consumer electronics industry and geographically from Philippines.
<h3>Concentrix: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Concentrix's remarkable performance in 3 months is evident. As of 30 November, 2024, the company achieved an impressive revenue growth rate of 9.74%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Concentrix's net margin excels beyond industry benchmarks, reaching 4.54%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Concentrix's ROE stands out, surpassing industry averages. With an impressive ROE of 2.71%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Concentrix's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.92%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Concentrix's debt-to-equity ratio is below the industry average. With a ratio of 1.17, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

<h3>Gainers</h3>
<ul>
<li>Greenland Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTEC#NASDAQ">GTEC</a>) stock moved upwards by 63.4% to $2.14 during Thursday's regular session. The company's market cap stands at $29.0 million. The company's, Q4 earnings came out yesterday. </li>
<li>Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) shares increased by 35.59% to $61.94. The company's market cap stands at $3.9 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) stock moved upwards by 30.87% to $6.4. The market value of their outstanding shares is at $80.0 million. </li>
<li>Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) stock moved upwards by 19.27% to $4.12. The company's market cap stands at $1.2 billion. </li>
<li>Avis Budget Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) stock rose 18.96% to $73.22. The market value of their outstanding shares is at $2.5 billion. </li>
<li>Satellogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) stock increased by 13.6% to $4.26. The company's market cap stands at $411.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) stock decreased by 25.8% to $0.27 during Thursday's regular session. The market value of their outstanding shares is at $52.4 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) stock decreased by 20.68% to $0.25. The market value of their outstanding shares is at $3.8 million. </li>
<li>3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) stock decreased by 18.94% to $2.21. The company's market cap stands at $299.0 million. The company's, Q4 earnings came out yesterday. </li>
<li>Linkers Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKS#NASDAQ">LNKS</a>) shares decreased by 15.98% to $0.54. The company's market cap stands at $7.2 million. </li>
<li>HUHUTECH International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUHU#NASDAQ">HUHU</a>) shares decreased by 14.83% to $4.31. The company's market cap stands at $91.2 million. </li>
<li>SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares declined by 10.32% to $0.57. The company's market cap stands at $203.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BIYA

GTEC

HUHU

LNKS

LNZA

SATL

WLGS

12 Industrials Stocks Moving In Thursday's Intraday Session

WIIM

Concentrix shares are trading higher following better-than-expected Q1 financial results and Q2 revenue guidance above estimates. Additionally, B of A  Securities raised its price target on the stock from $58 to $59.

Barrington Research analyst Vincent Colicchio maintains Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) with a Outperform and maintains $54 price target.

Barrington Research Maintains Outperform on Concentrix, Maintains $54 Price Target

U.S. stocks were lower, with the Dow Jones index falling around 0.2% on Thursday.
Shares of Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance <a href="https://in.benzinga.com/news/earnings/25/03/44504468/concentrix-shares-pop-on-strong-q1-results-raised-revenue-guidance">above estimates</a>.
Concentrix reported quarterly earnings of $2.79 per share, which beat the analyst consensus estimate of $2.58. Quarterly revenue came in at $2.37 billion, which beat the analyst consensus estimate of $2.36 billion and is down slightly from revenue of $2.4 billion from the same period last year.
Concentrix raised its fiscal 2025 reported revenue outlook from between $9.47 billion and $9.61 billion to between $9.49 billion and $9.635 billion, versus the $9.54 billion estimate.
Concentrix shares jumped 27% to $58.28 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) shares jumped 40.3% to $68.72 after the company announced it secured FDA approval for its first commercial drug for a rare genetic disorder.</li>
<li>Petco Health and Wellness Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) gained 32% to $3.2399 following fourth-quarter results.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) rose 23.5% to $4.2650.</li>
<li>Jiayin Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) climbed 20.2% to $14.55 following fourth-quarter results.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) gained 19.7% to $73.72.</li>
<li>MillerKnoll, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) shares climbed 11.7% to $20.45 after reporting third-quarter results.</li>
<li>Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) rose 11.6% to $24.85.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) gained 11% to $3.0850.</li>
<li>iQIYI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) shares rose 8% to $2.4150.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 6.4% to $36.09. Cantor Fitzgerald analyst Li Watsek reiterated Zai Lab with an Overweight rating.</li>
<li>Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) rose 5.5% to $73.08. Telsey Advisory Group analyst Joseph Feldman maintained Dollar Tree with a Market Perform and raised the price target from $75 to $82.</li>
<li>Ollie&#8217;s Bargain Outlet Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) gained 4.7% to $113.24.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44492633/jim-cramer-palantir-is-a-winner-recommends-selling-this-tech-stock">Jim Cramer: Palantir Is A &#8216;Winner,&#8217; Recommends Selling This Tech Stock</a></li>
</ul>

Intraday Update

Markets

DLTR

EWTX

IBRX

JFIN

MLKN

OLLI

SLNO

WOOF

ZLAB

Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday

B of A Securities analyst Ruplu Bhattacharya maintains Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) with a Neutral and raises the price target from $58 to $59.

B of A Securities Maintains Neutral on Concentrix, Raises Price Target to $59

<h3>Gainers</h3>
<ul>
<li>Greenland Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTEC#NASDAQ">GTEC</a>) stock increased by 65.1% to $2.13 during Wednesday's after-market session. The market value of their outstanding shares is at $28.9 million. As per the news, the Q4 earnings report came out today. </li>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) shares rose 43.65% to $0.46. The market value of their outstanding shares is at $8.2 million. </li>
<li>Lakeside Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSH#NASDAQ">LSH</a>) shares moved upwards by 12.5% to $1.35. The company's market cap stands at $10.1 million. </li>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares rose 12.38% to $0.6. The company's market cap stands at $7.6 million. </li>
<li>Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) stock rose 10.66% to $50.55. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q1 earnings came out today. </li>
<li>Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) shares moved upwards by 10.0% to $11.66. The market value of their outstanding shares is at $1.3 billion. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) stock fell 24.3% to $0.1 during Wednesday's after-market session. </li>
<li>Aeries Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AERT#NASDAQ">AERT</a>) shares declined by 20.83% to $0.54. The market value of their outstanding shares is at $24.0 million. </li>
<li>ConnectM Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) shares fell 10.36% to $0.56. The market value of their outstanding shares is at $16.2 million. </li>
<li>3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) stock decreased by 7.36% to $2.52. The company's market cap stands at $341.7 million. As per the press release, Q4 earnings came out today. </li>
<li>Samfine Creation Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFHG#NASDAQ">SFHG</a>) stock declined by 6.95% to $0.67. The market value of their outstanding shares is at $14.9 million. </li>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) stock decreased by 5.22% to $4.36. The market value of their outstanding shares is at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Advanced Environmental Recycling Technologies

AERT

AREB

BGLC

CNTM

LICN

SFHG

UGRO

12 Industrials Stocks Moving In Wednesday's After-Market Session

Concentrix Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) released its first-quarter results after Wednesday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/03/g44502934/concentrix-reports-first-quarter-2025-results">from the quarter. </a>
The Details: Concentrix reported quarterly earnings of $2.79 per share, which beat the analyst consensus estimate of $2.58. Quarterly revenue came in at $2.37 billion, which beat the analyst consensus estimate of $2.36 billion and is down slightly from revenue of $2.4 billion from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/global/25/03/44494896/us-adds-50-chinese-entities-to-export-restriction-list-curtailing-access-to-nvidia-amd-chips">US Adds 50 Chinese Entities To Export Restriction List Curtailing Access To Nvidia, AMD Chips</a>
&#8220;Our first quarter results demonstrate our progress as we win quality business and take advantage of GenAI opportunities, leveraging our unique technology and service capabilities to drive our clients&#8217; success,&#8221; said Chris Caldwell, CEO of Concentrix. 
&#8220;With a solid start to the year, we remain on track to deliver ongoing constant currency revenue growth, while expanding margins and growing free cash flow in 2025 and beyond,&#8221; Caldwell added.
Outlook:&nbsp;Concentrix raised its fiscal 2025 reported revenue outlook from between $9.47 billion&nbsp;and $9.61 billion to between&nbsp;$9.49 billion and $9.635 billion, versus the&nbsp;$9.54 billion estimate. The company continues to see fiscal year adjusted EPS of $11.18 to $11.77 per share, versus the $11.44 estimate. 
CNXC Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Concentrix shares were up 11.15% after-hours at $50.77 Wednesday.  
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/03/44477467/trumps-tariffs-on-buyers-of-venezuelan-oil-could-boost-energy-sector-exxon-mobil-stock">Trump&#8217;s Tariffs On Buyers Of Venezuelan Oil Could Boost Energy Sector, Exxon Mobil Stock&nbsp;</a></li>
</ul>
Image: Shutterstock

Earnings

After-Hours Center

Tech

Concentrix Shares Pop On Strong Q1 Results, Raised Revenue Guidance

Based on current exchange rates, the expectations assume an approximate 135-basis point negative impact of foreign exchange rates compared with the prior year. The guidance implies constant currency revenue growth for the full year of 0% to 1.5%.
Operating income of $669 million to $709 million and non-GAAP operating income of $1.300 billion to $1.340 billion.
In addition, the Company expects to generate approximately $625 million to $650 million of adjusted free cash flow in fiscal year 2025.

Guidance

Concentrix Raises FY25 Reported Revenue Outlook From $9.47B - $9.61B To $9.49B - $9.635B (Est $9.543B), Continues To See Adj EPS Of $11.18 - $11.77 (Est $11.44)

Concentrix shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 revenue guidance above estimates.

Based on current exchange rates, these expectations assume an approximate 90-basis point negative impact of foreign exchange rates compared with the prior year period. The guidance implies constant currency revenue growth for the quarter ranging from 0.50% to 1.25%.
Operating income of $155 million to $165 million and non-GAAP operating income of $315 million to $325 million.
&nbsp;

Concentrix Expects Q2 Reported Revenue Of $2.37B - $2.39B (Est $2.365B), Adj EPS Of $2.69 - $2.80 (Est $2.78)

Concentrix Expects To Return More Than $240M To Shareholders In FY25 Through Share Repurchases And Dividends

Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) reported quarterly earnings of $2.79 per share which beat the analyst consensus estimate of $2.58 by 8.14 percent. This is a 8.56 percent increase over earnings of $2.57 per share from the same period last year. The company reported quarterly sales of $2.37 billion which beat the analyst consensus estimate of $2.36 billion by 0.33 percent. This is a 1.28 percent decrease over sales of $2.40 billion the same period last year.

Earnings Beats

Concentrix Q1 2025 Adj EPS $2.79 Beats $2.58 Estimate, Sales $2.37B Beat $2.36B Estimate

<h3>Companies Reporting Before The Bell</h3>
• Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) is estimated to report quarterly loss at $5.00 per share on revenue of $5.60 million. 
• Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) is projected to report quarterly earnings at $2.18 per share on revenue of $8.23 billion. 
• Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $3.20 billion. 
• Titan America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTAM#NYSE">TTAM</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $384.72 million. 
• Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) is likely to report quarterly earnings at $1.06 per share on revenue of $2.60 billion. 
• SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) is expected to report quarterly loss at $0.03 per share on revenue of $202.71 million. 
• REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $152.00 million. 
• CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $358 thousand. 
• Target Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $80.10 million. 
• JinkoSolar Holding Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) is estimated to report quarterly loss at $0.46 per share on revenue of $3.59 billion. 
• BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is expected to report quarterly earnings at $0.62 per share on revenue of $1.35 billion. 
• Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) is expected to report quarterly loss at $0.14 per share on revenue of $88.50 million. 
• Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) is expected to report quarterly loss at $2.94 per share on revenue of $4.28 million. 
• Cheetah Mobile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMCM#NYSE">CMCM</a>) is expected to report earnings for its fourth quarter. 
• Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) is projected to report quarterly earnings at $1.48 per share on revenue of $1.51 billion. 
• Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Snail (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAL#NASDAQ">SNAL</a>) is estimated to report earnings for its fourth quarter. 
• Integra Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#AMEX">ITRG</a>) is likely to report earnings for its fourth quarter. 
• TAT Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) is likely to report earnings for its fourth quarter. 
• Envela (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELA#AMEX">ELA</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $40.63 million. 
• 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) is projected to report quarterly loss at $0.11 per share on revenue of $114.96 million. 
• BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) is projected to report quarterly loss at $0.87 per share on revenue of $20 thousand. 
• Oxbridge Re Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXBR#NASDAQ">OXBR</a>) is projected to report earnings for its fourth quarter. 
• Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $6.91 million. 
• Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $14.21 million. 
• Zepp Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>) is expected to report earnings for its fourth quarter. 
• FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) is projected to report quarterly loss at $0.03 per share on revenue of $33.09 million. 
• Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) is projected to report quarterly earnings at $1.13 per share on revenue of $1.97 billion. 
• Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $2.10 million. 
• H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $797.68 million. 
• Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is expected to report quarterly loss at $0.06 per share on revenue of $1.35 million. 
• Usio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USIO#NASDAQ">USIO</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $21.40 million. 
• Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) is estimated to report quarterly earnings at $1.27 per share on revenue of $276.82 million. 
• Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is estimated to report quarterly earnings at $3.01 per share on revenue of $2.47 billion. 
• Spruce Power Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) is projected to report earnings for its fourth quarter. 
• Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $790.90 million. 
• Guardian Pharmacy Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $320.52 million. 
• Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) is expected to report quarterly loss at $0.26 per share on revenue of $232 thousand. 
• MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $918.88 million. 
• Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $87.50 million. 
• Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) is estimated to report earnings for its Fiscal Year 2024. 
• Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $1.56 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALUR

ALVO

BCDA

CATX

CHWY

CLGN

CMCM

CTAS

DERM

DOOO

DRRX

DTIL

DYAI

GRDN

ITRG

MVIS

OXBR

PAYX

SAIL

SNAL

Spruce Power Holding Corporation Class A Common Stock

SPRU

TATT

TTAM

USIO

VRNT

ZEPP

Earnings Scheduled For March 26, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Chardan Capital slashed Century Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) price target from $11 to $7. Chardan Capital analyst Geulah Livshits maintained a Buy rating. Century Therapeutics shares closed at $0.5550 on Friday. <a href="https://www.benzinga.com/quote/IPSC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut the price target for Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) from $296 to $269. Piper Sandler analyst Peter Keith maintained an Overweight rating. Lowe&#8217;s shares closed at $227.07 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/LOW/analyst-ratings">view this stock</a>.</li>
<li>JP Morgan boosted Alnylam Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) price target from $280 to $328. JP Morgan analyst Jessica Fye upgraded the stock from Neutral to Overweight. Alnylam Pharmaceuticals shares closed at $283.34 on Friday. <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies cut the price target for FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) from $300 to $275. Jefferies analyst Stephanie Moore upgraded the stock from Hold to Buy. FedEx shares closed at $230.33 on Friday. <a href="https://www.benzinga.com/quote/FDX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barrington Research lowered the price target for Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) from $70 to $54. Barrington Research analyst Vincent Colicchio maintained an Outperform rating. Concentrix shares closed at $44.93 on Friday. <a href="https://www.benzinga.com/quote/CNXC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group cut RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) price target from $500 to $420. Telsey Advisory Group analyst Cristina Fernandez maintained an Outperform rating. RH shares settled at $242.18 on Friday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group cut Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) price target from $159 to $131. Evercore ISI Group analyst Stephen Kim downgraded the stock from Outperform to In-Line. Lennar shares closed at $115.22 on Friday. <a href="https://www.benzinga.com/quote/LEN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim raised Pinterest, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) price target from $39 to $40. Guggenheim analyst Michael Morris upgraded the stock from Neutral to Buy. Pinterest shares closed at $32.42 on Friday.  <a href="https://www.benzinga.com/quote/PINS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James cut the price target for Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) from $96 to $82. Raymond James analyst Simon Leopold upgraded the stock from Outperform to Strong Buy. Lumentum shares settled at $66.61 on Friday. <a href="https://www.benzinga.com/quote/LITE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) price target from $30 to $31. Stifel analyst Steven Wieczynski maintained a Buy rating. Carnival shares closed at $20.94 on Friday. <a href="https://www.benzinga.com/quote/CCL/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44454777/top-3-risk-off-stocks-that-may-explode-this-month-2">Top 3 Risk Off Stocks That May Explode This Month</a></li>
</ul>

Pre-Market Outlook

ALNY

IPSC

LITE

PINS

Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday

Barrington Research analyst Vincent Colicchio maintains Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) with a Outperform and lowers the price target from $70 to $54.

Barrington Research Maintains Outperform on Concentrix, Lowers Price Target to $54

Mark Cuban extended his support to President Donald Trump&#8216;s new &#8216;Gold Card&#8217; scheme to obtain U.S. citizenship if these cards were sold to corporations who hire immigrants. Billionaire entrepreneur and Dallas Mavericks owner added that the &#8220;H1b Visa game is ridiculous.&#8221;
What Happened: <a href="https://www.benzinga.com/news/25/02/43985233/mark-cuban-calls-deductibles-the-biggest-problem-in-healthcare-system-needs-to-be-redesigned">Cuban</a> proposed a new way for high-skilled workers to obtain U.S. citizenship in his latest X post.
Agreeing with President Trump on generating revenue via handing over citizenships, Cuban added that corporations could pay $5 million for an employee earning over $500,000 per year to get immediate citizenship, provided they pass a thorough background check.
Cuban argues that if a person is highly valuable to a company, the company should be willing to pay for the right to employ them in the U.S. He further suggests that if companies are not going to hire American workers, they should at least contribute to the tax base for the privilege of hiring foreign talent.
The billionaire investor also believes the current H-1B visa system, which uses a lottery and has caps, is &#8220;broken.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I ACTUALLY LIKE THIS IDEA IF WE SELL THEM TO CORPORATIONS. The H1b Visa game is ridiculous. Go to companies and tell them, $5m for any employee making over 500k, and they get immediate citizenship if they pass an advanced background check. Without citizenship , and only 3… <a href="https://t.co/O0xlSUVrBW">https://t.co/O0xlSUVrBW</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1896398624482841050?ref_src=twsrc%5Etfw">March 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
This comes after Trump addressed the amount of revenue that could be generated via selling &#8216;Gold Cards&#8217; during a press conference. He said, &#8220;If we sell a million &#8211; that&#8217;s $5 trillion… if we sell 10 million, that&#8217;s $50 trillion. That means our debt is totally paid off, and we have $15 trillion above that.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/25/02/44038874/nvidia-wipes-375-billion-of-investor-wealth-in-2025-margin-of-error-razor-thin-says-analyst-reiterating-buy-on-dips-call">Nvidia Wipes $375 Billion Of Investor Wealth In 2025: &#8216;Margin Of Error Razor Thin,&#8217; Says Analyst Reiterating &#8216;Buy On Dips&#8217; Call</a>
Why It Matters: As the President and corporate tycoons agree to generate revenue via this route, a 2024 report by the American Immigration Council highlighted that immigrant entrepreneurs make up 22.6% of all entrepreneurs nationwide.
According to the study, from the New American companies that made the 2024 Fortune 500 list, 46%, or 230 companies, were founded by immigrants or their children and each company employs about 67,332 workers.
Here are the names of a few listed entities that are new entrants in the Fortune 500 list, hiring and led by immigrants.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>)</td>
<td>11.44%</td>
<td>-5.80%</td>
</tr>
<tr>
<td>EchoStar Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>)</td>
<td>37.27%</td>
<td>139.31%</td>
</tr>
<tr>
<td>DoorDash Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>)</td>
<td>16.28%</td>
<td>49.88%</td>
</tr>
<tr>
<td>Microchip Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>)</td>
<td>3.48%</td>
<td>-32.28%</td>
</tr>
<tr>
<td>Prologis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>)</td>
<td>18.86%</td>
<td>-7.25%</td>
</tr>
<tr>
<td>Interactive Brokers Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>)</td>
<td>12%</td>
<td>84.04%</td>
</tr>
<tr>
<td>Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>)</td>
<td>12.88%</td>
<td>2.38%</td>
</tr>
<tr>
<td>Monster Beverage Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>)</td>
<td>4.47%</td>
<td>-6.58%</td>
</tr>
<tr>
<td>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)</td>
<td>37.97%</td>
<td>-61.41%</td>
</tr>
<tr>
<td>Concentrix Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>)</td>
<td>3.72%</td>
<td>-36.66%</td>
</tr>
</tbody>
</table>
</figure>
Apart from these, the &#8216;Magnificent 7,&#8217; &#8216;Big Tech&#8217; and other U.S. giants also hire many immigrants and they can boost the U.S. government revenue by purchasing &#8216;Gold Cards&#8217; for their talented and deserving employees as suggested by Mark Cuban.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose on Friday. The SPY was up 1.56% to $594.18, and the QQQ also advanced 1.56% to $508.10, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44034837/soundhound-ais-polaris-outperforms-google-and-openai-forays-in-energy-sector-with-seven-figure-deal-amid-q4-beat">SoundHound AI Says Polaris Speech Recognition Model Outperforms Google, OpenAI: Company Forays Into Energy Sector With 7-Figure Deal</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Politics

DASH

GEHC

IBKR

MCHP

MNST

SATS

SMCI

Mark Cuban Supports Trump's New 'Gold Card' Scheme If Sold To Corporations For Employee Citizenship: Here're The Listed-Companies With Most Number Of Immigrants

Press Releases

Concentrix Schedules Release of First Quarter 2025 Financial Results and Webcast of Investor Conference Call

Concentrix Reports First Quarter 2025 Results

Varonis and Concentrix Forge Partnership to Deliver Data Security for the AI Revolution

Concentrix Named a Leader in Everest Group's Trust and Safety Services PEAK Matrix® Assessment for Fifth Consecutive Year

General

Concentrix Launches CyberProtect Managed Service Offering

Concentrix to Present at Upcoming Investor Conferences

Concentrix Releases Independent Survey Results: Enterprise Priorities and Generative AI Adoption

Concentrix Launches iX Hero™ Agentic AI Apps to Solve Critical Pain Points of the Customer Experience

Concentrix Rises to #426 on the 2025 Fortune 500® List

Concentrix Schedules Release of Second Quarter 2025 Financial Results and Webcast of Investor Conference Call

Comments

Concentrix

ニュース

パートナーシップ

ベンジンガ・グローバル